600276.SS Jiangsu Hengrui Medicine Co Ltd Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
News✓
Loading...
All directions✓
▲ Long✓
▼ Short✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
06:40
Apr 27
Rebecca Liang Reporter, The Block Bloomberg Markets
Long Innovent Biologics and Hengrui Medicine.
She recommends Innovent Biologics and Hengrui Medicine as top picks in the Chinese pharmaceutical sector. Innovent is a maturing biopharma transitioning to global level with a strong pipeline and deal-making capability. Hengrui is a traditional company successfully phasing out legacy products and replenishing with innovative drugs. Both have clinical catalysts and are positioned to benefit from China's growing dominance in global drug R&D.
600276.SS
HIGH

About 600276.SS Analyst Coverage

Buzzberg tracks 600276.SS (Jiangsu Hengrui Medicine Co Ltd) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 1 total trade ideas tracked.